Gray haired woman in blue shirt smiles into the camera.

Blood Clotting Therapies At
THE HEART OF HUMAN RESILIENCE.

Hemab is pioneering the first targeted preventative treatments and functional cures for underserved bleeding and thrombotic disorders—reimagining the standard of care for patients everywhere.

Our Approach

No Patient With A
Clotting Disorder

SHOULD BE
LEFT BEHIND.
While patients with common bleeding and thrombotic disorders have had access to preventative treatments for more than a half-century, no such measures exist for less-common disorders.
Young girl with glasses in a yellow sweater smiles into the camera.
For these tens of thousands of men, women, and children, life is paralyzingly unpredictable. A bleeding or thrombotic event can strike any moment, from a simple menstrual period to a routine dental procedure, and cause symptoms so severe that by the time they reach a hospital, it may be too late.
It’s time to ensure that every clotting disorder patient has the security and peace of mind they deserve.

The First-Ever Preventative Treatments For

RARE CLOTTING DISORDERS.
Hemab is leapfrogging technological advancements to deliver the first ever prophylactic treatments and functional cures for the full spectrum of genetically driven bleeding and thrombotic disorders to prevent life-threatening complications and offer patients a new lifeline. 
Essentially, the body’s bleeding and thrombosis pathway is fine-tuned, and there are numerous points within it that can fail, causing disease. Our novel therapies are designed to accumulate, modulate/balance, and at times recruit endogenous clotting factors already present in the blood to the site of injury to enable patients to form hemostatic plugs (or, clots) at the right times and in the right places.
Man with glasses in a gray sweater smiles into the camera.
Our therapeutic candidates* bind the body’s native clotting factor(s) with high specificity and affinity. This binding can stabilize the native clotting factor(s), preventing breakdown and allowing accumulation to therapeutic levels. Furthermore, the binding can be neutral (preserving the activity of the native clotting factor) or inhibitory (inactivating the clotting factor), giving us the versatility to address challenges across the clotting pathway. Our state-of-the-art technology also allows us, when necessary, to recruit native clotting factors directly to the site of injury.  
Man in green shirt hugs woman in gray sweater, both smiling into camera.

*Currently using monovalent and bispecific antibodies, with intention of expanding to other modalities

Our Pipeline

Preventing The Full Spectrum Of

BLEEDING & THROMBOTIC EVENTS.

Leveraging validated advanced technologies and key insights into the biology of clotting, Hemab’s approach is prime for widespread expansion into a range of underserved bleeding and thrombotic disorders, including Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and others.

Man in a tan shirt smiles into the camera.

We are committed to finding and serving patients that have been left behind despite recent innovative therapies. Our strategic guidance, Hemab 1-2-5TM is targeting development of five clinical assets by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, active lives.

Hemab 1-2-5TM: 5 Clinical Assets by 2025
Program
Discovery
Preclinical
PI
PII
Program
Discovery
Preclinical
Phase I
Phase II
HMB-001 (Bleeding)
Lead candidate HMB-001 is a bispecific antibody that binds, stabilizes, and recruits endogenous factor VIIa (FVIIa) to the site of vascular injury to overcome the body’s inability to form healthy clots—building on the longstanding efficacy of recombinant FVIIa with the benefit of prophylaxis. Indicated for Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome
HMB-VWF (Bleeding)
HMB-VWF is designed as a prophylactic treatment for Von Willebrand Disease Type 1 and 2
HMB-TAF (Bleeding)
HMB-TAF is designed as a prophylactic treatment for Hereditary Hemorrhagic Telangiectasia and disorders of hyperfibrinolysis
HMB-AT3 (Thrombosis)
HMB-AT3 is designed as a prophylactic treatment for antithrombin (AT) deficiency
HMB-TBA

If you have questions about our ongoing clinical trials, please contact clinicaltrials@hemab.com.

Our expanded access policy can be found here.

Our Team

Building The Ultimate
CLOTTING COMPANY.

Bringing together international experts in clotting biology, patient care, and drug development, the Hemab team is committed to changing the lives of patients with rare clotting disorders all around the world.

Young girl in a cheek-to-cheek hug with her mother, both smiling into the camera.
Benny Sorensen, MD, PhD
CEO
Mads Behrndt​, MSc
CFO & General Manager
Cécile Bonvoisin, MSc
Senior Vice President, CMC and Manufacturing
John Maraganore​, PhD
Board Chair
Linda Bain​
Director
Dan Becker, MD, PhD
Director
Uya Chuluunbaatar, PhD
Director
Jørgen Søberg Petersen, MD, PhD, DMSc, MBA
Director
Benny Sorensen, MD, PhD
Director
Mårten Steen, MD, PhD
Director
Laura Tadvalkar​, PhD, MSc
Director
Akshay Vaishnaw, MD, PhD
Director
Christine Borowski, PhD
Observer
Camilla Petrycer Hansen, PhD, Cand. Pharm
Observer
Shan Wang, PhD
Observer
Jigar Amin, PharmD
Director of Medical Affairs and Global External Engagement
Erik Bjornson
Vice President of Regulatory Affairs
Amalie Carnbring Bonde, PhD
Research Scientist
Heidi Dyreborg
Senior Accountant
Prafull Gandhi, PhD, MS
Scientific Director
Shea Golden
Senior Clinical Research Associate
Ashley Gosnell, MPAS, PA-C
Senior Manager, Clinical Research
Mattias Häger, PhD, MSc
Scientific Director
Rane Harrison, PhD
Director of Analytical Development
Klaus Krainer Jønsson, MSc
Finance Director
Louise Kempf-Amkær
Senior Laboratory Technician
Shivangi Mathy
Associate Director of Clinical Operations
Helle Elisabeth Gluver Nørgaard
Senior Laboratory Technician
Henrik Østergaard, PhD, MSc
Vice President, Research
Emil Poulsen, MSc
Director, Drug Substance Development, CMC
Dr. Catherine Rea, MD, PhD
Senior Director, Clinical Research
Thanh-Hue Tran, MSc
Finance Manager
Joe Vogel
Senior Director of Clinical and Program Leadership
Rebecca A. Young, MPH
Director of Clinical Operations